According to a study published in the journal Nature Medicine, researchers analyzing 51 longitudinal intervention studies in the TranslAGE database have discovered why certain epigenetic aging biomarkers track biological changes far more reliably than others. Clocks trained to predict mortality or the pace of aging showed the strongest responsiveness across lifestyle and pharmacological longevity interventions, offering a potential pathway to shorten clinical trial durations.
Translating Epigenetic Clocks Through Standardized Databases
To systematically compare how biological aging responds to treatments, researchers curated the TranslAGE database, incorporating data from public repositories like the European Molecular Biology Laboratory (EMBL) and the Gene Expression Omnibus (GEO), alongside private clinical trials from TruDiagnostic, according to the Nature Medicine study. The team calculated 16 distinct epigenetic clocks alongside 94 DNA methylation (DNAm) biomarkers to observe underlying biological pathways.
First-generation clocks like Horvath and Hannum were evaluated alongside second-generation models such as PhenoAge, DunedinPoAm38, and GrimAgeV1. Researchers also utilized explainable clocks—generation X biomarkers including OMICmAge, DNAmEMRAge, and SystemsAge. By standardizing age-adjusted values across datasets, the study established a uniform baseline to compare pre- and post-intervention blood samples using paired t-tests.
Pharmacological and Lifestyle Interventions Drive Biomarker Responsiveness
Out of the interventions examined, 19 significantly decreased DNAm aging measures, while five showed significant increases, with the remainder yielding no notable effect, according to the published findings. Pharmacological and lifestyle modifications drove the strongest biomarker responses, with drugs producing larger average effect sizes. Specific pharmacological agents, including metformin, produced strong alterations in DNAm biomarkers, particularly impacting inflammatory, brain, and metabolic system scores through explainable models.
Did you know?
Explainable clocks use multiple subscores to provide targeted biological insight into specific organ systems, outperforming traditional single-score epigenetic clocks in pinpointing how interventions affect distinct physiological pathways.
Population Health Status and Drug Class Variations
Study population characteristics and duration heavily influenced biomarker responsiveness, according to the data. Biomarkers showed sharper decreases in studies involving participants with existing diseases compared to healthy cohorts. Notably, tumor necrosis factor (TNF)-targeting therapies modified almost second-generation DNAm biomarkers uniformly among individuals with arthritis or inflammatory bowel disease (IBD).
Conversely, other popular longevity interventions displayed varied consistency. While two forms of the Mediterranean diet lowered second-generation biomarkers in healthy participants, five separate senolytic drug studies showed divergent changes across multiple DNAm biomarkers, indicating inconsistent effects on epigenetic aging.
Implications for Future Clinical Trials in Geroscience
Reliable generation 2+ DNAm biomarkers—such as GrimAgeV2, PCGrimAge, SystemsAge, DunedinPACE, and PCPhenoAge—demonstrated significant drops across multiple trials. DunedinPACE showed the greatest overall responsiveness, while PCGrimAge provided the strongest statistical evidence, according to the research team. These responsive biomarkers could eventually serve as surrogate endpoints, helping researchers evaluate anti-aging interventions rapidly without waiting decades for traditional morbidity and mortality endpoints.
However, the study authors emphasized that biomarker responsiveness alone does not prove an intervention slows aging or validate a biomarker as a surrogate endpoint. Future clinical trials must link these DNAm changes directly with long-term healthspan and lifespan outcomes.
Frequently Asked Questions
What are epigenetic clocks?
Epigenetic clocks are biochemical tests that measure DNA methylation levels to estimate biological age rather than chronological age.
Which epigenetic biomarkers responded best to interventions?
According to the Nature Medicine study, clocks trained to predict mortality or the pace of aging—such as DunedinPACE and PCGrimAge—demonstrated the most consistent responsiveness.
Can epigenetic biomarkers replace long-term clinical trials right now?
Not yet. While they offer a way to monitor short-term changes, researchers stress that biomarker shifts must be linked to long-term clinical outcomes before they can serve as validated surrogate endpoints.
Stay Informed on Longevity Science
Subscribe to our research updates to receive the latest findings on geroscience, clinical trials, and biological aging biomarkers directly in your inbox.
Related reading